GMTX

Gemini Therapeutics, Inc. (GMTX) | Rumor.io

Gemini Therapeutics

GMTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio-14.5

Market capitalization520.3M

Earnings per share-4.49

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-71.9M

Social

What share of all stock conversation is about GMTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 23

Gemini Therapeutics, Inc. (GMTX) is being promoted in a farming-themed campaign, with messages encouraging support and participation.
The campaign is tracking a "kut hamayti" (support count), with various messages mentioning the number of supporters and encouraging others to join.
The tone of the messages is enthusiastic and motivational, with phrases such as "beh beh ajab chieh" (what a great thing) and "midevim va mirsim" (we're on our way).

Generated by AI

Sentiment

Of the messages about GMTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	33.33% -66.67
Bearish	—	—	—	66.67% +66.67

Bullish· Dec 16

$GMTX has the potential for a 800% upside, according to H.C. Wainwright, with an average price target of $20 per share.
Gemini Therapeutics has a significant market opportunity in treating age-related macular degeneration, with an estimated global market size of $7.75 billion in 2020.
The company's cash on hand is significantly higher than its current stock value, with $150 million in cash compared to a current market value of $118 million.

Bearish· Dec 16

The company's stock price has gapped down from $10 and is likely to be filled soon.
The stock has broken support and may continue to run lower, with some traders waiting patiently for it to fall back to its current price of under $3.
The company's cash value is significantly higher than its current stock price, suggesting that the stock may be undervalued.

Generated by AI

Topics

Of the messages about GMTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Analysts· Mar 1

Gemini Therapeutics, Inc. ($GMTX) was downgraded to Hold from Buy at Jefferies Financial Group, with a price target lowered to $1.50 from $23.
HC Wainwright cut Gemini Therapeutics' price target to $5 from $20, and Jefferies downgraded the stock to Hold with a price target of $1.50.
The downgrade by Jefferies Financial Group and HC Wainwright's price target cut to $5 from $20 have contributed to Gemini Therapeutics' extended losses.

Announcements· Jan 4

Gemini Therapeutics, Inc. ($GMTX) filed SEC forms 3 and 4 for various directors and executives, including the acquisition of new securities.
Insiders at Gemini Therapeutics, Inc. ($GMTX) made 10 new insider trades, including Orbimed Advisors Llc, Atlas Venture Fund X, L.p., and several directors.
Gemini Therapeutics, Inc. ($GMTX) filed a Form SC 13D/A and 4 new form 3 filings with the SEC, detailing beneficial ownership of securities.

Generated by AI

Community

Of the messages about GMTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Also Discussed

Investors talking about GMTX also mention

#	Name	Attention
1	Disc Medicine, Inc.IRON	0%new
2	Claritev CorporationMPLN	0%0
3	Enliven Therapeutics, Inc.ELVN	0%0
4	GRTX - Galera Therapeutics, Inc.	——
5	Theravance Biopharma Inc.TBPH	0%new
6	Foghorn Therapeutics Inc.FHTX	0%new
7	Passage Bio Inc.PASG	0%0
8	Cumberland Pharmaceuticals Inc.CPIX	0%new
9	ATHA - Athira Pharma, Inc.	——
10	Society Pass IncorporatedSOPA	0%0